The US Supreme Court preserved but narrowed an inventor’s right to later argue that their patent is not valid in the second high court case this month to weigh on the biopharma intellectual property landscape.
The Pharmaceutical Research and Manufacturers of America had filed an amicus brief arguing for complete preservation of the doctrine of “assignor estoppel,” which prevents inventors from later nullifying their own patents, so the limitations imposed by the Supreme Court in the